Congqiao Zhao

A phase I randomized, <scp>double‐blinded</scp>, <scp>placebo‐controlled</scp> study assessing the safety and pharmacokinetics of <scp>RIPK1</scp> inhibitor <scp>GFH312</scp> in healthy subjects

Jason D. Lickliter, Shuang Wang, Wenxin Zhang et al. · Clinical and Translational Science · 2023 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors

Ye Guo, Zishu Wang, Huan Zhou et al. · BMC Cancer · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17

A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.

Xinghao Ai, Aiping Zhou, Lin Wu et al. · Journal of Clinical Oncology · 2025 · 12 citations

Medicine, Oncology, Pharmacology +8